Somagenetix AG, a pioneering biotech company focussing on gene therapies for disorders affecting a type of white blood cells, raised CHF 10 million in a first closing of its Series A financing round. The funds will enable Somagenetix to advance its leading gene therapy-candidate, SGX-001, into a clinical trial.